Trade Report: The Argos Therapeutics Inc. (ARGS) gets Hold status at Zacks Investment Research

The Argos Therapeutics Inc. (ARGS) gets Hold status at Zacks Investment Research

Zacks Investment Research cut shares of Argos Therapeutics Inc. (NASDAQ:ARGS) from a buy rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Argos Therapeutics is a biopharmaceutical company which focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis (TM) technology platform. Argos Therapeutics is based in Durham, United States. “

ARGS has been the subject of a number of other research reports. Piper Jaffray Cos. reiterated an overweight rating and set a $11.00 price objective on shares of Argos Therapeutics in a research report on Monday, June 20th. FBR & Co reiterated a buy rating on shares of Argos Therapeutics in a research report on Tuesday, June 14th. Finally, Needham & Company LLC reiterated a buy rating and set a $11.00 price objective on shares of Argos Therapeutics in a research report on Friday, June 17th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Argos Therapeutics currently has a consensus rating of Buy and an average target price of $11.50.

Shares of Argos Therapeutics (NASDAQ:ARGS) opened at 4.89 on Tuesday. The firm’s market capitalization is $201.45 million. Argos Therapeutics has a 52 week low of $1.61 and a 52 week high of $13.97. The firm’s 50-day moving average is $4.88 and its 200 day moving average is $5.92.

Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. On average, equities analysts forecast that Argos Therapeutics will post ($1.56) earnings per share for the current year.

In other news, major shareholder International S. Pharmstandard acquired 67,371 shares of Argos Therapeutics stock in a transaction dated Wednesday, August 24th. The shares were acquired at an average cost of $4.52 per share, with a total value of $304,516.92. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder International S. Pharmstandard acquired 43,618 shares of Argos Therapeutics stock in a transaction dated Thursday, September 29th. The stock was purchased at an average cost of $4.56 per share, for a total transaction of $198,898.08. The disclosure for this purchase can be found here. 61.64% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Fund Advisors raised its position in Argos Therapeutics by 880.1% in the second quarter. BlackRock Fund Advisors now owns 281,679 shares of the biopharmaceutical company’s stock valued at $1,727,000 after buying an additional 252,940 shares in the last quarter. Vanguard Group Inc. raised its position in Argos Therapeutics by 57.2% in the second quarter. Vanguard Group Inc. now owns 377,497 shares of the biopharmaceutical company’s stock valued at $2,314,000 after buying an additional 137,390 shares in the last quarter. State Street Corp purchased a new position in Argos Therapeutics during the second quarter valued at $741,000. BlackRock Institutional Trust Company N.A. purchased a new position in Argos Therapeutics during the second quarter valued at $363,000. Finally, Oxford Asset Management purchased a new position in Argos Therapeutics during the second quarter valued at $353,000. 11.05% of the stock is currently owned by institutional investors and hedge funds.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Related posts

Leave a Comment